You are here: Industry Insights > REGN-COV2

News List

Regeneron, NIAID Begin REGN-COV2 Phase 3 COVID-19 Prevention Trial americanpharmaceuticalreview
July 15, 2020
Regeneron Pharmaceuticals announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19.
Phase III COVID-19 antibody trials initiated in Americas europeanpharmaceuticalreview
July 10, 2020
Simultaneous Phase III trials evaluating Regeneron’s REGN-COV2 antibody as both a prophylactic and a treatment have begun in US and some South American locations.
Regeneron Awarded $450M BARDA Contract contractpharma
July 08, 2020
To manufacture and supply anti-viral antibody cocktail REGN-COV2 for the potential treatment of COVID-19.
Regeneron Starts Phase 3 Trial for Coronavirus Antibody Cocktail contractpharma
July 07, 2020
Anti-viral antibody cocktail REGN-COV2 is also in Phase 2/3 treatment trials following positive Phase 1 safety review.
Regeneron Begins Trials of Anti-Viral Antibody Cocktail for COVID-19 americanpharmaceuticalreview
June 22, 2020
Regeneron Pharmaceuticals announced initiation of the first clinical trial of REGN-COV2, its investigational dual antibody cocktail for the prevention and treatment of COVID-19.
Regeneron Begins Clinical Trials of Anti-Viral Antibody Cocktail contractpharma
June 16, 2020
REGN-COV2 is targeted specifically against SARS-CoV-2.

Previous page 1 2 Next page